370 related articles for article (PubMed ID: 30528147)
21. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Kasmeridis C; Lip GY; Apostolakis S
Hosp Pract (1995); 2013 Feb; 41(1):61-70. PubMed ID: 23466968
[TBL] [Abstract][Full Text] [Related]
22. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Eriksson BI; Quinlan DJ; Eikelboom JW
Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
[TBL] [Abstract][Full Text] [Related]
23. Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis.
Schurgers LJ; Spronk HM
Thromb Haemost; 2014 Nov; 112(5):909-17. PubMed ID: 25298033
[TBL] [Abstract][Full Text] [Related]
24. Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.
McCarty D; Robinson A
Ther Adv Cardiovasc Dis; 2016 Feb; 10(1):37-49. PubMed ID: 26378211
[TBL] [Abstract][Full Text] [Related]
25. Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.
Saraf K; Morris PD; Garg P; Sheridan P; Storey R
Postgrad Med J; 2014 Sep; 90(1067):520-8. PubMed ID: 25085900
[TBL] [Abstract][Full Text] [Related]
26. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
27. A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation?
Riva N; Lip GY
Pol Arch Med Wewn; 2012; 122(1-2):45-53. PubMed ID: 22353706
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
Vamos M; Cappato R; Marchlinski FE; Natale A; Hohnloser SH
Europace; 2016 Dec; 18(12):1787-1794. PubMed ID: 26797248
[TBL] [Abstract][Full Text] [Related]
29. Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke.
Diener HC; Ntaios G; O'Donnell M; Easton JD
Expert Opin Pharmacother; 2018 Oct; 19(14):1597-1602. PubMed ID: 30152249
[TBL] [Abstract][Full Text] [Related]
30. New oral anticoagulants: comparative pharmacology with vitamin K antagonists.
Scaglione F
Clin Pharmacokinet; 2013 Feb; 52(2):69-82. PubMed ID: 23292752
[TBL] [Abstract][Full Text] [Related]
31. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
Marcy TR; Truong T; Rai A
Consult Pharm; 2015 Nov; 30(11):644-56. PubMed ID: 26629800
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
[TBL] [Abstract][Full Text] [Related]
33. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.
Enriquez A; Lip GY; Baranchuk A
Europace; 2016 Jul; 18(7):955-64. PubMed ID: 25816811
[TBL] [Abstract][Full Text] [Related]
34. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Waks JW; Zimetbaum PJ
Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
[TBL] [Abstract][Full Text] [Related]
36. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.
; Bousser MG; Bouthier J; Büller HR; Cohen AT; Crijns H; Davidson BL; Halperin J; Hankey G; Levy S; Pengo V; Prandoni P; Prins MH; Tomkowski W; Torp-Pedersen C; Wyse DG
Lancet; 2008 Jan; 371(9609):315-21. PubMed ID: 18294998
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
38. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Senoo K; Lip GY
Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
Barra ME; Fanikos J; Connors JM; Sylvester KW; Piazza G; Goldhaber SZ
Am J Med; 2016 Nov; 129(11):1198-1204. PubMed ID: 27341955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
